The contribution of Fc-mediated effector functions to the therapeutic efficacy of some
monoclonal antibodies has motivated efforts to enhance interactions with Fcγ receptors …

Monoclonal antibodies (mAb) are widely used in the treatment of non-Hodgkin's lymphoma
and autoimmune diseases. Although the mechanism of action in vivo is not always known …

Antibodies are now recognized as key therapeutic tools to combat most forms of malignancy.
Although the first wave of therapeutic antibodies that emerged over two decades ago directly …

Highlights•The antibody Fc domain engages immune-activating, inhibitory, and homeostatic
Fc receptors.•Fc domains are largely unaltered in existing therapeutic antibodies, whether to …

Antibody-dependent cell-mediated cytotoxicity, a key effector function for the clinical efficacy
of monoclonal antibodies, is mediated primarily through a set of closely related Fcγ …

The discovery of both cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and
programmed cell death protein 1 (PD1) as negative regulators of antitumour immunity led to …

The function of the low-affinity IgG-receptor FcγRIIIb (CD16b), which is uniquely and
abundantly expressed on human granulocytes, is not clear. Unlike the other Fcγ receptors …

Fc γ receptor (FcγR) coengagement can facilitate antibody-mediated receptor activation in
target cells. In particular, agonistic antibodies that target tumor necrosis factor receptor …

The binding of IgG to receptors for the Fc region of IgG (FcγR) is a critical step for the
initiation and the control of effector immune functions. Activating FcγR induce antibody …

Given the widespread use of antibodies of the immunoglobulin G (IgG) class as cytotoxic,
immunomodulatory, and neutralizing agents in the therapy of malignant, infectious, and …